Aggregator

赤ちゃんの速い呼吸(新生児一過性多呼吸)に対処するための治療法

3 years 3 months ago
赤ちゃんの速い呼吸(新生児一過性多呼吸)に対処するための治療法 レビューの論点 呼吸が異常に速い赤ちゃん(新生児一過性多呼吸と呼ばれる)に対する薬物やその他の治療は、肺機能を改善し、呼吸補助(つまり人工呼吸)の必要性や症状の持続時間を減らすことができるか? 背景 新生児の一過性多呼吸(異常に速い呼吸)(TTN)は、呼吸数の増加(1分間に60回以上)と呼吸が苦しそうに見える(呼吸困難)の兆候が特徴である。たいていは、妊娠34週目以降に生まれた赤ちゃんの生後2時間以内に現れる。新生児の一過性多呼吸は、通常、治療をしなくても改善するが、小児期後半になると肺の喘鳴を伴うことがある。このコクランオーバービューレビュー(系統的レビューを対象としたレビュー)は、新生児の一過性多呼吸の管理に対するさまざまな治療の有益性と有害性に関する利用可能なエビデンスを報告し、批判的に分析したものである。 研究の特徴 6 件のコクランレビューを対象とした。そのうち4件は薬物(サルブタモール、エピネフリン、副腎皮質ステロイド(薬)(以下,ステロイド)、利尿剤)とプラセボを比較し、残りの2件は肺に管を挿入せずに少ない量の輸液と呼吸(呼吸器)サポートを与えることの効果を評価したものである。サルブタモール、エピネフリン、ステロイドは肺の余分な水分を取り除き、利尿剤は肺の水分を尿に排出するのを促進する薬である。 エビデ...

University of Sydney seek Postdoc Research Associate

3 years 3 months ago
  • Full time fixed term until February 2023 (possibility of extension)
  • Great opportunity for an early career researcher to join a supportive and well respected team, making an impact in health based research
  • Base Salary $98,645 + 17% superannuation
  • Applications Close: Sunday 27 February 2022

About the opportunity
The NHMRC Clinical Trials Centre has an exciting opportunity for a Postdoctoral Research Associate to contribute to a range of projects using NextGen evidence synthesis methodologies and conducting meta-research.

Projects will likely include; finding and implementing ideal strategies in childhood obesity prevention interventions with the TOPCHILD collaboration, assessing eating disorder risk in obesity treatment, and conducting meta-research to find and reduce reasons for research waste and increase collaboration and coordination in research.

This is a research-only position, based at the NHMRC Clinical Trials Centre. The successful applicant will be working in the NextGen Evidence Synthesis team within the Evidence Integration Team. There will be an opportunity to develop NextGen evidence synthesis specialist skills, and to attend academic conferences to present project work. The successful applicant will be expected to make an active contribution to papers and new grant submissions arising from this work.

Your key responsibilities will be to:

  • undertake systematic reviews
  • work on individual participant data meta-analyses with large data sets
  • work with a large number of international collaborators and other stakeholders.

About you

  • a strong research background including a PhD qualification and competitive publication track record in a relevant field (systematic reviews, obesity, neonatology, epidemiology, public health, quantitative research or biostatistics)
  • formal qualifications in research methods, such as Masters level qualifications in epidemiology, biostatistics or public health is highly desired
  • ability to work independently, conceive, initiate, organise and manage projects
  • excellent communication and interpersonal skills
  • the successful applicant will combine quantitative research skills with excellent communication and scientific writing skills
  • experience in systematic reviews and meta-analyses is highly desirable
  • experience in research implementation and communication with a broad range of stakeholders (e.g. policy makers, consumers) is desirable, but not essential.

To keep our community safe, please be aware of our COVID safety precautions which form our conditions of entry for all staff, students and visitors coming to campus.

Sponsorship/work rights for Australia
Please note: Visa sponsorship is not available for this position. For a continuing position, you must be an Australian or New Zealand citizen or an Australian Permanent Resident.

Australian Temporary Residents currently employed at the University of Sydney may be considered for a fixed term contract for the length of their visa, depending on the requirements of the hiring area and the position.

Pre-employment checks
Your employment is conditional upon the completion of all role required pre-employment or background checks in terms satisfactory to the University. Similarly, your ongoing employment is conditional upon the satisfactory maintenance of all relevant clearances and background check requirements. If you do not meet these conditions, the University may take any necessary step, including the termination of your employment.

EEO statement
At the University of Sydney, our shared values include diversity and inclusion and we strive to be a place where everyone can thrive. We are committed to creating a University community which reflects the wider community that we serve. We deliver on this commitment through our people and culture programs, as well as key strategies to increase participation and support the careers of Aboriginal and Torres Strait Islander People, women, people living with a disability, people from culturally and linguistically diverse backgrounds, and those who identify as LGBTIQ. We welcome applications from candidates from all backgrounds.

How to apply

  • Applications (including a cover letter, CV, and any additional supporting documentation) can be submitted here 
  • If you are a current employee of the University or a contingent worker with access to Workday, please login into your Workday account and navigate to the Career icon on your Dashboard.  Click on USYD Find Jobs and apply.
  • For a confidential discussion about the role, or if you require reasonable adjustment or support filling out this application, please contact Lena Germinarios, Recruitment Operations, by email to lena.germinarios@sydney.edu.au
  • The University reserves the right not to proceed with any appointment.
  • Click to view the Position Description for this role.
  • Applications Close Sunday 27 February 2022 11:59 PM
Tuesday, February 22, 2022 Category: Jobs
Lydia Parsonson

卵巣がんの初回治療でのパクリタキセル投与を週1回にすると、3週に1回よりも生存期間が改善するか

3 years 3 months ago
卵巣がんの初回治療でのパクリタキセル投与を週1回にすると、3週に1回よりも生存期間が改善するか 背景 卵巣がんは世界で6番目に多いがんである。治療は外科手術と化学療法(パクリタキセルとカルボプラチンがもっとも一般的)が併用される。併用の目的はがんの再発の確率を減少または再発を遅延させること(無増悪生存期間(PFS)の延長)と、延命(全生存期間(OS)の延長)である。パクリタキセルの投与スケジュール(頻度)が治療効果に与える影響を検討した臨床試験が複数あるが、報告されている結果は相反するものである。 本レビューの目的 卵巣がんの新規診断患者に対するパクリタキセルの投与頻度の差が生存期間に与える影響について、エビデンスのレビューを行った。 研究の特性 エビデンスは2021年11月15日現在のものである。計3,699人が参加した4件の研究をレビュー対象とした。いずれの研究も18歳以上の卵巣がんの新規診断患者を対象としたランダム化比較試験(患者が2群以上の治療群のいずれかにランダムに割り付けられる試験)である。各試験は、カルボプラチンと併用するパクリタキセルについて週1回投与と3週に1回投与を比較している。 主な結果 カルボプラチンと併用するパクリタキセルを3週に1回投与した場合に比べ、週に1回投与した場合、全生存期間にはほとんど差がないものの、無増悪生存期間がわずかに延長する可能性が高...

Cochrane seeks Cochrane Clinical Answers Editor

3 years 3 months ago

Specifications: Part time (0.5FTE) Permanent/Consultancy contract dependant on location
Salary: £48,500 per annum full time equivalent
Location: Remote, flexible
Application Closing Date:  Friday 4 March 2022

We are looking for a part-time editor to join the Cochrane Clinical Answers (CCA) team.

CCAs provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane Reviews. They are designed to be actionable and to inform point-of-care decision-making and are published in the Cochrane Library (cochranelibrary.com).

Working with the CCA team, the editor will:

  • develop and edit a derivative product that supports the relevance and applicability of Cochrane Reviews, and their presentation and delivery to healthcare professionals;
  • ensure content is developed to best practice, delivered to agreed publishing date, and is consistent with Cochrane’s vision and values;
  • support the CCA Senior Editor with the editorial work and processes of the CCA team (including the CCA Editor in Chief and Cochrane’s publisher), with the aim of improving quality and efficiency through systems and guidance.

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information.

For this role, an understanding of Cochrane’s work and health research more generally is an advantage, but not essential.

The majority of Cochrane Central Executive staff are based in London, UK, but we will consider candidates from any location.



How to apply

  • For further information on the role and how to apply, please click here.  
  • The deadline to receive your application is by Friday 4 March.  
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Interviews to be held on: tbc
Thursday, February 17, 2022 Category: Jobs
Lydia Parsonson

体圧分散型椅子は褥瘡予防に有効か?

3 years 3 months ago
体圧分散型椅子は褥瘡予防に有効か? 要点 包括的な検索を実施したが、体圧分散型椅子が褥瘡の予防や管理に役立つかどうかを調べた研究は見つからなかった。これは重要なテーマであり、このような椅子が褥瘡を発症するリスクのある人々に有益かどうかを判断するために、質の高い研究が必要である。 褥瘡とは何か? 褥瘡は、長時間の圧迫により皮膚やその下の組織に生じる傷である。座ることは回復の過程で重要な役割を果たすが、長時間座ることは褥瘡の発生リスクを高める。 褥瘡はどのように管理されているのか? 長時間座っているときにかかる皮膚への圧力を分散させることを目的としたクッションや表面素材が使用される。車いすに体圧分散クッションを使用した場合の効果については、一般的な椅子よりも研究が多く存在する。 現在、体圧分散型椅子が標準的な椅子と比較して、リスクのある人々の褥瘡を予防または管理するためにどの程度効果的であるかは分かっていない。 体圧分散型椅子には、クッションや手動または機械で動かす機能がない一般的な病院用椅子や住宅用椅子から、体圧分散をする素材を使用し、人が座るとリクライニング、起き上がり、チルトの機能があるものまで、さまざまなものがある。これらは、標準的なデザインで製作するか、または、その人のニーズに合わせたオーダーメイドのデザインも可能である。 何を知りたかったのか? 医療、リハビリテーション、...

PARP阻害薬は卵巣がん患者の生存率を改善するか、またその副作用は何か

3 years 3 months ago
PARP阻害薬は卵巣がん患者の生存率を改善するか、またその副作用は何か 要点 化学療法終了後の治療(維持療法)として毎日服用する錠剤のPARP(ポリ(ADPリボース)ポリメラーゼ)阻害薬については、有効成分を含まない「ダミー」の薬(プラセボ)と比較すると、次のことが言える。 - 進行上皮性卵巣がん患者の全生存期間を延長する効果はほとんどないと思われる(ただし、この結果はさらに多くのデータが出てくれば変わる可能性がある) - 新たに上皮性卵巣がんと診断された患者では、病勢進行を遅らせる可能性が高い - プラチナ製剤感受性の上皮性卵巣がんの再発患者では、病勢進行を遅らせる可能性が高い - 重度の副作用のリスクを増加させる可能性が高い 病勢進行を遅らせることでQOLに有益な影響を及ぼすかどうかは、報告されたデータに矛盾がみられるため非常に不確かである。しかし少量のデータから、PARP阻害薬が病勢進行を遅らせることにより病気の症状を改善する可能性があることが示唆される。 上皮性卵巣がんとは何か 上皮性卵巣がんは、卵巣、卵管、腹腔(腹膜)の内膜(上皮)から発生するがんである。がん細胞が腹腔内に入りやすいため、多くの場合、上皮性卵巣がんは進行期で発見される。初期治療は手術(理想的には目に見える病変をすべて切除する)と化学療法の組み合わせである。しかし、ほとんどの患者は再発するため、さらに治療...

成人の人工股関節置換術

3 years 3 months ago
成人の人工股関節置換術 このレビューでは、成人の大腿骨近位部骨折の治療に用いられる様々なタイプの人工股関節置換術の有益性と有害性に関して、ランダム化比較試験(RCT)および準RCTにおけるエビデンスを評価した。 背景 大腿骨近位部骨折は、足の骨の付け根が折れることである。このような骨折は、骨粗鬆症という状態で骨がもろくなっている高齢者によく見られる。治療法のひとつに、折れた股関節を人工股関節に置き換えるという方法がある。これは、股関節の一部(関節のボール部分)を置き換える半関節形成術(HA)で実施することができる。これらの人工関節には、ユニポーラ(単一の人工関節)とバイポーラ(追加の関節を持つもの)がある。また、手術によって股関節全体(股関節の球が収まる受け皿の部分も含む)を置き換えることもある。これが全人工股関節置換術(THA)である。これらの人工関節は、いずれも骨セメントを使用して固定することも、使用せずに固定することも可能である。 検索日 2020年7月6日までのRCT(治療群に無作為に割り付ける臨床研究)、および準RCT(生年月日や病院の記録番号など無作為化されていない方法で群に入れる)を検索した。 研究の特徴 10,654人の成人、10,662の大腿骨近位部骨折を対象とした58件の研究を対象とした。研究参加者の年齢は63歳から87歳で、71%が女性であったが、これは、こ...

乳歯の齲蝕予防を目的とするシーラント

3 years 3 months ago
乳歯の齲蝕予防を目的とするシーラント レビューの論点 乳臼歯の噛み合わせ面にシーラントを塗ると、そこに虫歯ができるのを防げるか? 背景 虫歯は、小児の健康全般に影響を及ぼす小児期の代表的な病気の一つである。最もよく影響を受けるのは奥歯で、噛む面が平らでなく、溝(ピット(小孔)やフィッシャー(亀裂))があるため、食べ物のカスや細菌を留めてしまい、虫歯(齲蝕)の形成につながる。また、これらの溝の開口部は非常に小さく、歯ブラシの毛が完全に入らないため、清掃が困難である。溝を塞ぐことは、奥歯の虫歯を防ぐ方法の一つである。シーラントは、食べ物や細菌に対する防護壁の役割を果たし、歯の表面に有害な作用が及ぶのを防ぐ。 研究の特徴 1,120人の小児(18か月から8歳まで)が参加した9件の研究を対象とした。乳歯の虫歯予防のために、さまざまなシーラントを使った研究が行われている。結果(評価項目)を測定している歯科専門家は、シーラントが適用されているかどうかを見ることができ、また、シーラントの材料を識別できたため、ほとんどの研究は、全体的にバイアスのリスクが高いと評価した。 主な結果 3件の研究ではシーラントとシーラントなしを比較し、6件の研究では歯の表面をシールする異なる材料やプロセスを比較した。シーラントの種類、試験開始時の子どもの年齢、追跡期間の長さなど、研究デザインに重要な差があったため、デ...

Cochrane EPOC seek Systematic Reviewer

3 years 3 months ago

Location: Oxford
Salary: £33,309 to £40,927
Hours: Part Time
Contract Type: Fixed-Term/Contract
Closes: 11th March 2022
Job Ref: 155759

Oxford Population Health (The Nuffield Department of Population Health) contains world-renowned population health research groups and provides an excellent environment for multi-disciplinary research and teaching. The Clinical Trial Service Unit is a major international research institute within Oxford Population Health, and is one of the world’s leading centres for research into chronic diseases, such as cancer and heart disease.

As a Systematic Reviewer you will work with the Cochrane Effective Practice and Organisation of Care (EPOC) group in a multidisciplinary research environment. You will provide systematic review expertise to authors of ongoing EPOC systematic reviews, and take a lead or collaborate with existing authors on completing and publishing high priority EPOC reviews.

To be considered you will have a PhD in a health related subject (or equivalent experience), an understanding of statistics and experience of conducting and publishing systematic reviews. You will also have strong quantitative skills the ability to communication clearly with others.

  • Apply for the role here
  • The post is part-time (between 60-80%FTE) and fixed term to 31st March 2023.
  • The closing date for completed applications is 12.00 noon on 11th March 2022.   
  • Contact Email :recruit@ndph.ox.ac.uk
Thursday, February 10, 2022 Category: Jobs
Lydia Parsonson

Cochrane Connects Event, 1 March – Register Now

3 years 3 months ago

Register for Cochrane Connects meeting on research waste, including Cochrane-REWARD prize ceremony, and research integrity

Cochrane Connects - 1 March 17:00 – 18:00 GMT (check in your time zone)Register Now

Join us for the next Cochrane Connects meeting, which will focus on research waste and research integrity.

This special edition of Cochrane Connects will feature the Cochrane-REWARD prize ceremony. Since 2017, the prize has gathered, assessed and publicized local or pilot initiatives with the potential to reduce research waste if scaled up globally. We will be joined by representatives of the external prize committee, who will announce the winners of the first and second prizes live. The winners will share more about their initiatives in short presentations and answer audience questions.



There will also be an update on Cochrane’s research integrity activities from Senior Research Integrity Editor Prof Lisa Bero, followed by an opportunity for interactive discussion on what more Cochrane could do in this area, and on research waste in the future.

Cochrane Connects is a series of free online events open to everyone. You will have the opportunity to meet colleagues and peers, hear about and celebrate achievements from the community and take part in active discussions to help shape Cochrane for the future.

Register now by following the link here.

Monday, February 14, 2022
Lydia Parsonson

高齢者の大腿骨近位部(股関節)外側骨折の治療には、どのようなものがあるのか?

3 years 3 months ago
高齢者の大腿骨近位部(股関節)外側骨折の治療には、どのようなものがあるのか? 要点 - このタイプの股関節の骨折には、「最善な治療法」はない。 - コンジロセファリックネイル(condylocephalic nails:膝から股関節に向かって上向きに釘を刺す方法)や静的固定アングルプレート(ピンやネジで骨折した骨にプレートを取り付ける方法)による治療後に、骨折した股関節の再手術が必要になった人が多かった。 - ショートセファロメデュラリーネイル(short cephalomedullary nail:股関節から膝に向かって下向きに釘を刺す方法)と動的固定アングルプレート(骨折した骨にプレートを取り付けるピンやネジがスリーブの中でスライドできる方法)に違いがない可能性がある。 - しかし、どの治療法も術後のQOL(生活の質)を向上させるのに優れているかどうかを知るには、研究数が少なすぎた。 高齢者における大腿骨近位部(股関節)の骨折 大腿骨近位部骨折は、足の骨の付け根が折れることである。大腿骨近位部骨折には2つのタイプがあり、今回のレビューでは、股関節のすぐ外側で骨折(大腿骨転子部骨折)した人を対象とした。大腿骨近位部骨折のもう一つのタイプは、骨頭(ボール)と骨盤の窪み(ソケット)の関節のすぐ下の骨折(大腿骨頚部骨折)である。この骨折については、別のレビューで紹介した。どちらの骨折...

心的外傷後ストレス障害(PTSD)を予防するための薬

3 years 3 months ago
心的外傷後ストレス障害(PTSD)を予防するための薬 このレビューの重要性 心的外傷後ストレス障害(Post-traumatic stress disorder: PTSD)は、心的外傷(トラウマ)となるような出来事を経験した人が発症する可能性のある、重度で障害のある状態である。このような出来事は、それを経験した人だけでなく、彼らの大切な人の人生にも長期にわたって悪影響を及ぼす。 研究の結果、PTSDの人の脳の働きには変化があることがわかっている。そのため、心的外傷となる出来事の直後に、この脳の変化を標的とした薬を使うことで、PTSDの発症を予防することを提案する研究者もいる。しかし、心的外傷となるような出来事を経験しても、大多数の人はPTSDを発症しない。したがって、心的外傷となるような出来事のすぐ後に投与できる薬は、副作用のリスクとPTSD発症のリスクのバランスを含めて、その有効性を慎重に評価する必要がある。 誰が利益を得るか? - 心的外傷になるような出来事にさらされた人とその家族、友人、恋人。 -精神保健サービスに携わる専門家。 - 外傷・救急医療に携わる専門家。 - 心的外傷の被害者や軍隊の退役軍人をケアする人々。 このレビューで明らかにしたいことは? 心的外傷(トラウマ)をもたらすような出来事にさらされた人にとって、心理的な症状の有無にかかわらず、ある薬は他の薬やプラ...

Millions of lives could be saved if health evidence and communication is put at forefront of pandemic preparedness

3 years 3 months ago

New Cochrane Convenes report recommends urgent action among those who fund, generate and use evidence to ensure the world is better prepared.

Two years in, it is clear that COVID-19 has created an unprecedented focus on health evidence for people working in governments, businesses and non-governmental organizations as well as members of the public. Responsible governments and other bodies have “followed the science” or claimed to.

Since the early days of the pandemic, Cochrane and other research synthesis organizations have been curating and analysing the thousands of studies being published on COVID-19 to help decision makers make sense of the evidence. The arrival of Omicron reinforced the need for timely evidence as decision makers across the globe scrambled to guide healthcare services and the public once again.

Dr Karla Soares-Weiser, Editor in Chief, Cochrane explains, “Like many others, I have been deeply concerned about the widening of existing inequities and the way that those already vulnerable have been disproportionately affected by the pandemic. As a community of evidence producers and users, we were not as prepared to respond to the COVID-19 pandemic as we could have been.”

Seeking to learn from the experience, in October 2021, Cochrane, invited key thought leaders from around the world to reflect on their experiences of producing, sharing and using evidence during the pandemic. Working with co-sponsor WHO, and co-organizer COVID-END, the event was convened with a view to making a call to action on areas for improvement. A resulting report, published today, discusses the challenges faced and presents recommendations from the meeting.

The report highlights three major challenges:

  • The evidence response to the COVID-19 pandemic has been inequitable –in terms of the focus of the evidence, who has been producing it and who it reaches
  • Current scientific methods, tools and processes have been pushed to their limits in trying to answer questions at the speed demanded
  • In the face of an infodemic, researchers have struggled to communicate scientific uncertainties and gain trust in the evidence 

Over the course of 2022, Cochrane will engage with a wider group of experts to take forward the most pressing recommendations, including:

  • Building support for creation of evidence synthesis unit/s in low and middle-income countries to help address global imbalance. This will mean some of the world’s poorest communities will have access to relevant evidence on what works in their region.
  • Investing in science communications which will strengthen our ability to communicate uncertainty in a way citizens understand, as well as being more proactive about science communication. 
  • Strengthening of tools, methods, processes and relationships to ensure a rapid and relevant evidence response at national and global levels for the next global health emergency. 

The report also calls on other key stakeholders in evidence generation and use to take urgent action:

  • Funders to provide resources to meet national and international research needs, which must address inequities; and particularly to fund evidence generation, communication, networks and infrastructure in low- and middle-income countries
  • Politicians to demand evidence; be transparent about how (and what) evidence is used in decision making; and to hold to account those deliberately creating and sharing mis/disinformation 
  • Researchers to support research transparency and data sharing; and raise the alarm about fraudulent studies
  • Science communicators to learn what works in communicating uncertainty, generating trust in evidence and countering mis/disinformation

Dr John Grove, Director of the Quality assurance, norms and standards department, Science division. WHO HQ, said,

“WHO, with our clear global mandate, will continue to bring focus to the priority questions, design what is most relevant for countries, combat misinformation, push for reducing inequities of access to the best science, and redouble activities to lead and coordinate these aspects of the response. Our main platform will continue to be building out a living approach to guidance development and implementation.”

 
Dr Karla Soares-Weiser, Editor in Chief, Cochrane said,

"We have all seen how the COVID-19 pandemic and its wider impacts have claimed many lives around the world. Cochrane Convenes was organized out of a sense of responsibility to learn from our experiences of the evidence response so that we can be better equipped for future health emergencies. 

The Cochrane community is a powerful and diverse global network, which we can harness to drive change. Of course, we cannot, and will not, do this in isolation. I hope that this report is therefore a call to action to funders, political leaders and other parts of the research community to join us in taking the recommendations forward."

Wednesday, February 16, 2022
Muriah Umoquit

Cochrane seeks Evidence Synthesis Methodology Editor

3 years 3 months ago

Specifications: Permanent
Salary: circa £40,000 per annum
Location: UK
Application Closing Date:  Friday 25 February 2022

Cochrane’s Methods Support Unit was established in 2019 to provide methodological support in the production of high quality, high priority Cochrane systematic reviews.

The Methods Support Unit provides guidance and hands on statistical and methods support to Cochrane systematic reviews, including those using complex methods or non-randomised study designs. The unit comprises two part time Statistical Editors and one full time Evidence Synthesis Methodology Editor.  

As Evidence Synthesis Methodology Editor, you will provide methodological support and general systematic review methods advice for reviews in process, field queries from the Community Support Team, and provide methods peer review as requested. You may also be required to provide subject matter expertise for the development of specific features in tools and software used in the production of Cochrane Reviews.

The role will require a very good understanding of methods such as the assessment of risk of bias for different study designs, application of GRADE and interpretation of findings in the review. An understanding of statistical meta-analysis methods is advantageous in the role, although specialist statistical editors in the unit will be able to provide this advice.

The majority of Cochrane Central Executive staff are located in London, UK, however flexible location or a part-time appointment are possible for the right candidate.

How to apply

  • For further information on the role and how to apply, please click here.  
  • The deadline to receive your application is by Friday 25 February.  
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
Wednesday, February 9, 2022 Category: Jobs
Lydia Parsonson

Trusted information needs to be protected on social media as much as misinformation needs to be challenged

3 years 3 months ago

Recent removal of Cochrane’s Instagram post and shadowban highlight the realities of Cochrane’s call against misinformation

Cochrane’s health evidence syntheses are recognised as the international gold standard for high quality, trusted information. Our reviews are used to support global and national health guidelines and policy. We advocate for evidence-informed healthcare and make our trusted evidence accessible and available to all. One way we do this is using social media to reach different audiences. 

In recent days, Cochrane has again been the subject of an Instagram misinformation blunder, with a post about a Cochrane Review on Ivermectin for prevention and treatment of COVID-19 being removed from the platform. Also Cochrane’s Instagram account has been denied the verification blue check mark several times. We are aware that other research publishers, such as the BMJ, have also experienced similar issues.

The first time this happened in November, Cochrane’s Instagram account was ‘shadowbanned’ for a few weeks; people could not tag or mention @cochraneorg on the platform. While little specifics were given, there was a notification that the account ‘repeatedly posted content that goes against Community Guidelines on false content about COVID-19 or vaccines.’ This shadowban happened just days after Cochrane helped lead a campaign to tackle misinformation for World Evidence-Based Healthcare Day and launched a course with Lifeology about identifying and preventing infodemics.

“The removal of our Cochrane post on Instagram comes just days before the launch of the Cochrane Convenes Report which calls for generating trust in evidence and countering mis/disinformation.” says Cochrane’s Editor in Chief, Dr Karla Soares-Weiser.

Drawing on experiences of the COVID-19 pandemic, Cochrane Convenes brought together leaders in health research and health evidence to explore and recommend the changes needed in evidence synthesis to prepare for and respond to future global health emergencies. The full report of the recommendations is being released 16 February.

“It’s not clear if there is an issue with Instagram’s algorithm or if the issue lies with people ‘gaming’ policies and reporting posts as misinformation when they are not. What is clear is that there is an issue with how you hold those deliberately creating and sharing mis/disinformation to account and how you form accreditation and approval for official sources of evidence that have met certain quality control standards. We need to make it easier for people to access trustworthy information – and that includes on social media.”

Cochrane is a proud supporter of WHO’s call to action on infodemic management and is currently collaborating with science communicators at Lifeology and the Association for Healthcare Social Media  and welcomes the opportunity to work directly with social media platforms and with others interested in tackling misinformation.

 

Tuesday, February 8, 2022
Muriah Umoquit

Cochrane seeks Systems & Product Development Editor

3 years 3 months ago

Location: Flexible location (remote working) in the UK.
Specifications: Permanent contract.
Hours: Full-time week 37.5 hours.
Salary: £52,000 per annum.
Application Closing Date: 25 April

The Systems and Product Development Editor will provide strategic editorial and methods leadership to other departments to ensure editorial and methods strategy is reflected in Cochrane’s products, processes and technology.

The key purpose of the role is to deliver cross-departmental strategic objectives and targets by:

  1. Working closely with the Head of Change Management and Deputy Editor in Chief to help develop and deliver technological elements of Cochrane’s strategy for review production
  2. Providing editorial and methods oversight to align review production developments with Cochrane’s product development strategy
  3. Providing editorial and methods oversight to develop Cochrane’s review production systems and processes to deliver the review production strategy
  4. Engaging with members of the Cochrane community to help develop new products, systems and tools

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information.

Wednesday, April 13, 2022 Category: Jobs
Lydia Parsonson

Cochrane seeks Managing Editor

3 years 4 months ago

Specifications: Full Time (Fixed Term/Consultancy role)
Salary: circa £40,000 per annum
Location: Flexible
Application Closing Date:  Sunday 13 March 2022

Cochrane has established a centrally-resourced Editorial Service to support the efficient and timely publication of high-quality systematic reviews in the Cochrane Library. The reviews that are published through the Central Editorial Service address some of the research questions considered to be the most important to decision makers.

The Central Editorial Service is also running a pilot of approaches to increase editorial efficiency and integrity within Cochrane. The Managing Editor role will play a key role in operationalising this pilot.

Reporting to the Executive Editor of the Central Editorial Service, the Managing Editor will manage the editorial process of protocols and reviews submitted to the Central Editorial Service. The role-holder should be alert to the demands of delivering high-quality review content for publication in a timely fashion, and work to ensure that deadlines can be met.   

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information. An understanding of Cochrane’s work and health research more generally is an advantage, but not essential.

The majority of Cochrane Central Executive staff are located in London, UK, however flexible location or a part-time appointment are possible for the right candidate.

How to apply

  • For further information on the role and how to apply, please click here
  • The deadline to receive your application is by Sunday 13 March. 
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
Tuesday, March 1, 2022 Category: Jobs
Lydia Parsonson

脳卒中後のてんかん発作を予防するための抗てんかん薬の効果

3 years 4 months ago
脳卒中後のてんかん発作を予防するための抗てんかん薬の効果 レビューの論点 脳卒中後のてんかん発作を一次的あるいは二次的に予防するために抗てんかん薬(AEDs:antiepileptic drugs)の日常的な投与を支持するエビデンス(科学的根拠)はあるのだろうか?(一次予防:一度も発作のない状況での予防的な投薬、二次予防:一度発作があり、それ以降の再発作を予防するための投薬) 背景 脳卒中後のてんかん発作は臨床上重要である。成人脳卒中患者のてんかん発作予防に抗てんかん薬が有効かどうかは明らかではない。 結果 脳卒中後のてんかん発作の一次予防に関する抗てんかん薬を評価した、2件の前向きランダム化二重盲検プラセボ(偽薬)対照試験を見つけた。一件目は72人の成人を対象にバルプロ酸とプラセボとを比べた研究で、バルプロ酸のグループとプラセボのグループの間に脳卒中後のてんかん発作に差は見られなかった。二件目の研究は784人の成人を対象にジアゼパムとプラセボとを比べており、ジアゼパムのグループとプラセボのグループとの間に脳卒中後のてんかん発作に差は見られなかった。一方で、前方循環系(前大脳動脈や中大脳動脈など)の皮質性梗塞に限定したサブグループ解析では、脳卒中発症から3か月間は予防的なジアゼパムが有効である可能性を認めた。全体的にみると、脳卒中後のてんかん発作の予防を目的として抗てんかん薬を日...

Cochrane's 2022 International Women’s Day Events

3 years 4 months ago

In recognition of International Women's Day (IWD) happening March 8th, Cochrane will be hosting several events and activities. The IWD 2022 theme is “breaking gender bias and reducing stereotypes and discrimination to promote diversity, equity, and inclusion.”

The Annual Anne Anderson Walk is a cherished annual social event in Cochrane, where attendees walk to celebrate women's contributions to Cochrane while raising money to annual Anne Anderson Award.  Everyone is welcome to snap a picture of themselves and share their walk with the Community. Pictures will be posted on social media and the website as we encourage each other to get out on a walk - everyone is welcome to join in! 

Calling all science communicators and artists! Cochrane will be hosting an exciting challenge in collaboration with Lifeology. We would like to see your art and graphics that illustrate the IWD theme in relation to healthcare and/or evidence synthesis. 

Top submissions will be promoted on Cochrane social media pages and platforms, and the winner will be announced as part of the Cochrane US Women’s Day Panel and with an interview news item on Cochrane.org.  The winning graphic will also be used for a tote bag and mug, with credit to the creator, and will be available for purchase in the Cochrane Store.

Submission criteria:

  • Graphic should resonates with evidence synthesis / health science and this year’s IWD theme.  
  • .png file type preferred, full colour,  high resolution graphic with a DPI of 150
  • Follow @Cochrane_US on Twitter 
  • Email submission to tduque@cochrane.org with subject “IWD Graphic Submission”
  • Accepted until March 7, 2022

 

Join Cochrane US and Agency for Healthcare Research and Quality (AHRQ) for an enlightening and informative panel to highlight gender bias in health science and evidence synthesis. The panel will talk about their career, history, motivations, and encounters with gender bias.

Join Cochrane US and Cochrane Early Career Professionals Network (ECP) for an interactive hour of chats and speed networking.  Find out more about Cochrane, EPCs, and meet one-on-one virtually.  You'll get the opportunity to network with other attendees, with each random introduction only lasting 3 minutes. 

Únase a este evento especial gratuito con oradores de América Latina y España. Organizado por los participantes del Cochrane US Mentoring Program.

Friday, March 4, 2022
Muriah Umoquit

Cochrane Skin seeks 2 Systematic Reviewers - Nottingham, UK

3 years 4 months ago

Specifications: Fixed term post until 31 March 2023. Part or full-time. 
Location: Nottingham, UK
Salary: £27924 to £40927 per annum
Application deadline:
16 Feb 2022

A new opportunity has arisen for two Systematic Reviewers to join the Cochrane Skin team at its editorial base within the Centre of Evidence Based Dermatology (CEBD), School of Medicine, University of Nottingham. CEBD has an international reputation for research into the prevention and treatment of skin disease with a focus on delivering independent clinical research that informs the NHS.

Cochrane Skin is part of the international Cochrane organisation, and is the editorial base for the preparation and dissemination of Cochrane systematic reviews on the treatment and prevention of skin diseases. It is one of 62 Cochrane review groups worldwide which contribute to Cochrane, and this busy editorial base currently has around 20 review teams preparing protocols or reviews for publication or updating published reviews. In working as a Systematic Reviewer, you will lead and support systematic reviews within the Cochrane Skin portfolio in order to ensure the delivery of high-quality, timely evidence synthesis to support healthcare decision-making. You will be responsible for working with review teams to support title screening, data extraction, risk of bias assessment and contributing to the write-up of Cochrane Skin systematic reviews, and will ensure that your work adheres to relevant methodological guidance. 

They are seeking an individual with proven knowledge and experience of involvement in systematic reviews e.g. by participating as an author in a Cochrane systematic review or conducting a systematic review as a lead author. You should possess a good understanding of systematic review procedures, including knowledge of risk of bias assessment with an ability to critically appraise clinical trials. Excellent verbal and written communication skills, organisational skills and the ability to evaluate published clinical trial manuscripts are also essential. They particularly welcome applications from candidates with knowledge of Cochrane risk of bias 2.0 methodology.

Wednesday, February 2, 2022 Category: Jobs
Muriah Umoquit